Showing 101 - 120 results of 12,412 for search '(((( 50 c decrease ) OR ( 50 ((we decrease) OR (nn decrease)) ))) OR ( 12 men decrease ))', query time: 0.57s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104

    Neural networks classify states which differ in neuronal activity levels using ensembles of neurons that increase/decrease their activity in each state. by Nicholas A. Frost (10739821)

    Published 2021
    “…The hidden units have been ordered based on the output weights that are learned during classifier training. <b>(C)</b> After ordering the hidden units based on their output weight, we binned them into groups of 50. …”
  5. 105
  6. 106
  7. 107

    Presentation_1_Airway macrophages display decreased expression of receptors mediating and regulating scavenging in early cystic fibrosis lung disease.pdf by Lisa J. M. Slimmen (16464600)

    Published 2023
    “…</p>Methods<p>Bronchoalveolar lavage fluid (BALF) was collected from 50 children with CF aged 1, 3 or 5 years. BALF cells were analyzed using flow cytometry. …”
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115

    Design of Benzyl-triazolopyrimidine-Based NADPH Oxidase Inhibitors Leads to the Discovery of a Potent Dual Covalent NOX2/MAOB Inhibitor by Beatrice Noce (16540800)

    Published 2025
    “…We found that <b>9a</b>, bearing a pargyline moiety, is also able to selectively inhibit MAOB over MAOA (465-fold) with an IC<sub>50</sub> of 0.182 μM, being the first-in-class dual NOX2/MAOB covalent inhibitor. …”
  16. 116

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  17. 117

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  18. 118

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  19. 119

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…In this study, we report the first highly selective HDAC6 inhibitor with hydrazide as the zinc-binding group (ZBG), which displays superior pharmacokinetic properties to the current hydroxamic acid inhibitors. …”
  20. 120

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…In this study, we report the first highly selective HDAC6 inhibitor with hydrazide as the zinc-binding group (ZBG), which displays superior pharmacokinetic properties to the current hydroxamic acid inhibitors. …”